Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,accountsPayable,netReceivables,longTermDebt,deferredLongTermLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,changeToAccountReceivables,repurchaseOfStock,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2016) 4","Short Ratio (Jul 14, 2016) 4","Short % of Float (Jul 14, 2016) 4","Short % of Shares Outstanding (Jul 14, 2016) 4","Shares Short (prior month Jun 14, 2016) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,country,website,maxAge,address1,industry,address2
t0,EPRSQ,-6406000.0,26184300,10342000,,-16308000,,-16266000,6468000,803000,-16007000,-16007000,,-372000,,,,-42000,803000,16810000,0,-301000,,-16266000,-16266000,6211000.0,181126000.0,35175000.0,26166000.0,11321000.0,61341000.0,26000.0,1800000.0,-155025000.0,2548000.0,26361000.0,39000.0,380000.0,20865000.0,32627000.0,39000.0,2695000.0,25694000.0,3750000.0,,,,3490000.0,-70000.0,18000.0,-247000.0,18000.0,-10650000.0,17000.0,-10615000.0,287000.0,2121000.0,-70000.0,,,,-6933000.0,en-US,US,EQUITY,False,Delayed Quote,USD,EPIRUS BIOPHARMACEUTICALS INC,-0.5055739,157105,0.006006006,15,America/New_York,EDT,-14400000,False,False,REGULAR,0,4,0.006,1630503001,0.0,0.006,0.006,0.006,200,PNK,us_market,0.0,0.006 - 0.006,0.006,0.145,0.16,50,700,finmb_127289092,Other OTC,"EPIRUS Biopharmaceuticals, Inc.",USD,63651,42574,0.0038,1.7272727,0.0022 - 0.24,-0.234,-0.975,0.0022,0.24,-2.525,0.999,0.006847778,-0.0008477778,-0.12380335,0.012135282,-0.006135282,6.03,,,0.24,0.0022,0.0068,0.0121,63.65k,42.57k,26.18M,,21.73M,0.00%,0.00%,252.54k,0.07,1.08%,0.96%,524.87k,,,,,,0.00%,,,1:10,"Jul 15, 2014","Dec 30, 2015","Mar 30, 2016",0.00%,"-3,744.83%",-45.30%,-122.13%,1.48M,0.06,"3,112.00%",576k,-54.6M,-60.93M,-2.5250,,20.86M,0.8,14.85M,56.76,0.79,1.00,-49.01M,-17.83M,Value,02116,Healthcare,73,"EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.",Boston,617-600-3497,MA,United States,http://epirusbiopharma.com,86400,699 Boylston Street,Biotechnology,Eighth Floor
t-1,EPRSQ,3597000.0,26184300,8599000,,-15438000,,-15394000,5988000,285000,-14302000,-14302000,,-369000,,,,-44000,410000,14712000,125000,-1136000,,-15394000,-15394000,6410000.0,175126000.0,35896000.0,36368000.0,12394000.0,72264000.0,24000.0,653000.0,-138759000.0,2615000.0,26361000.0,-23000.0,2173000.0,31515000.0,33281000.0,-23000.0,2073000.0,35247000.0,2051000.0,130000.0,,,-965000.0,3533000.0,37000.0,-180000.0,355000.0,-12909000.0,-23000.0,-16456000.0,298000.0,-271000.0,-352000.0,56000.0,,,1966000.0,en-US,US,EQUITY,False,Delayed Quote,USD,EPIRUS BIOPHARMACEUTICALS INC,-0.5055739,157105,0.006006006,15,America/New_York,EDT,-14400000,False,False,REGULAR,0,4,0.006,1630503001,0.0,0.006,0.006,0.006,200,PNK,us_market,0.0,0.006 - 0.006,0.006,0.145,0.16,50,700,finmb_127289092,Other OTC,"EPIRUS Biopharmaceuticals, Inc.",USD,63651,42574,0.0038,1.7272727,0.0022 - 0.24,-0.234,-0.975,0.0022,0.24,-2.525,0.999,0.006847778,-0.0008477778,-0.12380335,0.012135282,-0.006135282,6.03,,,0.24,0.0022,0.0068,0.0121,63.65k,42.57k,26.18M,,21.73M,0.00%,0.00%,252.54k,0.07,1.08%,0.96%,524.87k,,,,,,0.00%,,,1:10,"Jul 15, 2014","Dec 30, 2015","Mar 30, 2016",0.00%,"-3,744.83%",-45.30%,-122.13%,1.48M,0.06,"3,112.00%",576k,-54.6M,-60.93M,-2.5250,,20.86M,0.8,14.85M,56.76,0.79,1.00,-49.01M,-17.83M,Value,02116,Healthcare,73,"EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.",Boston,617-600-3497,MA,United States,http://epirusbiopharma.com,86400,699 Boylston Street,Biotechnology,Eighth Floor
t-2,EPRSQ,17441000.0,26184300,7501000,,-14432000,,-13987000,3291000,221000,-10571000,-10571000,,-368000,,,,-445000,221000,10792000,0,-3861000,,-13987000,-13987000,5422000.0,174050000.0,36369000.0,50701000.0,9623000.0,87070000.0,24000.0,4103000.0,-123365000.0,2509000.0,27838000.0,-8000.0,2039000.0,44424000.0,21293000.0,-8000.0,1189000.0,50582000.0,2985000.0,217000.0,12567000.0,,817000.0,-2646000.0,73000.0,-398000.0,355000.0,-13864000.0,-23000.0,-11291000.0,110000.0,2223000.0,-79000.0,-56000.0,-245000.0,,29289000.0,en-US,US,EQUITY,False,Delayed Quote,USD,EPIRUS BIOPHARMACEUTICALS INC,-0.5055739,157105,0.006006006,15,America/New_York,EDT,-14400000,False,False,REGULAR,0,4,0.006,1630503001,0.0,0.006,0.006,0.006,200,PNK,us_market,0.0,0.006 - 0.006,0.006,0.145,0.16,50,700,finmb_127289092,Other OTC,"EPIRUS Biopharmaceuticals, Inc.",USD,63651,42574,0.0038,1.7272727,0.0022 - 0.24,-0.234,-0.975,0.0022,0.24,-2.525,0.999,0.006847778,-0.0008477778,-0.12380335,0.012135282,-0.006135282,6.03,,,0.24,0.0022,0.0068,0.0121,63.65k,42.57k,26.18M,,21.73M,0.00%,0.00%,252.54k,0.07,1.08%,0.96%,524.87k,,,,,,0.00%,,,1:10,"Jul 15, 2014","Dec 30, 2015","Mar 30, 2016",0.00%,"-3,744.83%",-45.30%,-122.13%,1.48M,0.06,"3,112.00%",576k,-54.6M,-60.93M,-2.5250,,20.86M,0.8,14.85M,56.76,0.79,1.00,-49.01M,-17.83M,Value,02116,Healthcare,73,"EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.",Boston,617-600-3497,MA,United States,http://epirusbiopharma.com,86400,699 Boylston Street,Biotechnology,Eighth Floor
t-3,EPRSQ,39253000.0,26184300,6475000,,-15329000,,-15286000,4600000,45000,-11030000,-11030000,,-315000,,,,-43000,45000,11075000,0,-4299000,,-15286000,-15286000,3492000.0,168462000.0,28373000.0,59108000.0,1709000.0,87481000.0,24000.0,,-109378000.0,4722000.0,16363000.0,,7540000.0,58288000.0,9733000.0,,673000.0,59413000.0,1860000.0,,13918000.0,5500000.0,-807000.0,-46000.0,7435000.0,4422000.0,355000.0,-3258000.0,-23000.0,-10647000.0,93000.0,931000.0,-46000.0,-56000.0,-65000.0,7500000.0,49680000.0,en-US,US,EQUITY,False,Delayed Quote,USD,EPIRUS BIOPHARMACEUTICALS INC,-0.5055739,157105,0.006006006,15,America/New_York,EDT,-14400000,False,False,REGULAR,0,4,0.006,1630503001,0.0,0.006,0.006,0.006,200,PNK,us_market,0.0,0.006 - 0.006,0.006,0.145,0.16,50,700,finmb_127289092,Other OTC,"EPIRUS Biopharmaceuticals, Inc.",USD,63651,42574,0.0038,1.7272727,0.0022 - 0.24,-0.234,-0.975,0.0022,0.24,-2.525,0.999,0.006847778,-0.0008477778,-0.12380335,0.012135282,-0.006135282,6.03,,,0.24,0.0022,0.0068,0.0121,63.65k,42.57k,26.18M,,21.73M,0.00%,0.00%,252.54k,0.07,1.08%,0.96%,524.87k,,,,,,0.00%,,,1:10,"Jul 15, 2014","Dec 30, 2015","Mar 30, 2016",0.00%,"-3,744.83%",-45.30%,-122.13%,1.48M,0.06,"3,112.00%",576k,-54.6M,-60.93M,-2.5250,,20.86M,0.8,14.85M,56.76,0.79,1.00,-49.01M,-17.83M,Value,02116,Healthcare,73,"EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.",Boston,617-600-3497,MA,United States,http://epirusbiopharma.com,86400,699 Boylston Street,Biotechnology,Eighth Floor
